Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".

Grimm M., van der Heijden A. G., Colombel M., Muilwijk T., Martinez-Pineiro L., Babjuk M. M., ...More

European urology, vol.78, no.5, pp.690-698, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 78 Issue: 5
  • Publication Date: 2020
  • Doi Number: 10.1016/j.eururo.2020.04.066
  • Journal Name: European urology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
  • Page Numbers: pp.690-698
  • Keywords: Bacillus Calmette-Guerin, Instillation therapy, Non-muscle-invasive bladder cancer, Reduced frequency, BACILLUS-CALMETTE-GUERIN, MITOMYCIN-C, TRANSURETHRAL RESECTION, FORMAL METAANALYSIS, CELL CARCINOMA, CANCER, RISK, PROGRESSION, T1, RECURRENCE
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Background: Intravesical instillation of bacillus Calmette-Guerin (BCG) is an accepted strategy to prevent recurrence of non-muscle-invasive bladder cancer (NMIBC) but associated with significant toxicity.